Previous 10 | Next 10 |
OpGen ( NASDAQ: OPGN ) announced Friday the preliminary second quarter estimates with revenue expected to be $1M, up from $0.8M in prior year. "We are excited by the progress made in the second quarter, especially the fact that in June we signed the first commercial contra...
Preliminary Total Revenue for Q2 2022 was approximately $1.0 million Cash as of June 30, 2022 was approximately $16.6 million First commercial customer contract for Acuitas AMR Gene Panel signed in June 2022 ROCKVILLE, Md., July 08, 2022 (GLOBE NEWSWIRE) -- O...
Results were published in the European Journal of Clinical Microbiology & Infectious Diseases Serial specimen analysis confirms correct detection of pathogens by Unyvero HPN Additional pathogens detected by Unyvero HPN confirmed in many instances by culture positivit...
Prospective multicenter trial for the Unyvero UTI panel recruited its 1,000 th prospective patient sample Fourth trial site added to optimize enrollment for different sample types and accelerate trial completion Clinical performance evaluation aims at a subse...
OpGen (NASDAQ:OPGN) said its unit Curetis signed an agreement with Leader Life Sciences for distribution of Unyvero systems in the United Arab Emirates ((U.A.E.)) and Qatar. Unyvero system is used for the diagnosis of infectious diseases. Under the agreement, Leader Life has exclusive rights ...
Exclusive distribution agreement for initial term of three years Leader Life Sciences commits to minimum purchase of 8 Unyvero systems during initial term Leader Life Sciences to seek regulatory clearance for Unyvero products in U.A.E. and Qatar ROCKVILLE, Md., June 09, 20...
3 Penny Stocks to Add to Your June 2022 Watchlist With the stock market mostly flat today, there is a lot for penny stocks traders to take advantage of. Although last week ended on a major high note, we are once again seeing volatility in the stock market. The main instigators of mo...
Diagnostic firm OpGen (NASDAQ:OPGN) stock rose 8.6% in premarket trading on Thursday after the company said its Unyvero Hospitalized Pneumonia (HPN) panel reduced the use of inappropriate antibiotic therapy by 39 hours in an interventional trial. Unyvero results combi...
208 patients enrolled in a prospective, randomized, controlled, multicenter, interventional trial Unyvero reduced the use of inappropriate antibiotic therapy by 45%, shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.5% ...
OpGen, Inc. (OPGN) Q1 2022 Earnings Conference Call May 12, 2022, 04:30 PM ET Company Participants Alyssa Factor - Edison Group Oliver Schacht - President and CEO Albert Weber - CFO Conference Call Participants Yi Chen - H.C. Wainwright Ben Haynor - Alliance Global Partners Presentation Opera...
News, Short Squeeze, Breakout and More Instantly...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...